Incretin Mimetics

*Prices reflect U.S. average retail price

Adlyxin (lixisenatide)

Lixisenatide (trade name Lyxumia in the Europe and Adlyxin in the U.S.) is a once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II. Initiate at 10 mcg once daily for 14 days. On Day 15, increase dosage to 20 mcg once daily... Wikipedia

 

Manufacturer's Website: Adlyxin                                                                                                                                    Average retail cost: $691/month

Bydureon (exenatide)

Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon... Wikipedia

 

Manufacturer's Website: Bydureon                                                                                                                            Average retail cost: $949/carton

Byetta (exenatide)

Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon... Wikipedia

 

Manufacturer's Website: Byetta                                                                                                                               Average retail cost: $9988/pen

Trulicity (dulaglutide)

Semaglutide (trade names Rybelsus, Ozempic) is a medication for the treatment of type 2 diabetes. Side effects include medullary thyroid cancer, kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis.

Semaglutide acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient. ... Wikipedia

 

Manufacturer's Website: Rybelsus                                                                                                                    Average retail cost: $1,104/month

Rybelsus (semaglutide)

Dulaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. It is used for the treatment of type 2 diabetes that can be used once weekly. GLP-1 is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The FDA approved dulaglutide for use in the United States in September 2014. The drug is manufactured by Eli Lilly under the brand name Trulicity... Wikipedia

 

Manufacturer's Website: Trulicity                                                                                                                        Average retail cost: $1,117/carton

Ozempic (Semaglutide)

Semaglutide (trade names Rybelsus, Ozempic) is a medication for the treatment of type 2 diabetes. Side effects include medullary thyroid cancer, kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis.... Wikipedia

 

Manufacturer's Website: Ozempic                                                                                                                      Average retail cost: $1,147/1 pen

Mounjaro (tirzepatide)

Tirzepatide, sold under the brand name Mounjaro, is an antidiabetic medication used for the treatment of type 2 diabetes... Wikipedia

 

Manufacturer's Website: Mounjaro                                                                                                                       Average retail cost: $1,233/carton

Victoza (liraglutide)

Liraglutide (NN2211) is a derivative of human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes... Wikipedia

 

Manufacturer's Website: Victoza                                                                                                                        Average retail cost: $1,345/carton

Wegovy (semaglutide)

Semaglutide (trade names Rybelsus, Ozempic) is a medication for the treatment of type 2 diabetes. Side effects include medullary thyroid cancer, kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis.

Semaglutide acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient. ... Wikipedia

 

Manufacturer's Website: Wegovy                                                                                                                   Average retail cost: $1,620/carton

Saxenda (liraglutide)

Liraglutide (NN2211) is a derivative of human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition... Wikipedia

 

Manufacturer's Website: Saxenda                                                                                                                 Average retail cost: $1,659/carton

Tanzeum (albiglutide)

Tanzeum has been discontinued by Manufactuer.

Copyright  2006---2023  Automated Clinical Guidelines, LLC.  All rights reserved.